INTEGRA LIFESCIENCES HOLDINGS CORPIART決算レポート
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
IART Q4 2025 Key Financial Metrics
売上高
$434.9M
粗利益
$220.9M
営業利益
$23.0M
純利益
N/A
粗利益率
50.8%
営業利益率
5.3%
純利益率
N/A
前年比成長
-1.7%
EPS
$-0.03
資金フロー
INTEGRA LIFESCIENCES HOLDINGS CORP Q4 2025 財務サマリー
INTEGRA LIFESCIENCES HOLDINGS CORP reported revenue of $434.9M (down 1.7% YoY) for Q4 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $214.1M, operating expenses totaled $197.8M.
主要財務指標
| 総売上高 | $434.9M |
|---|---|
| 純利益 | N/A |
| 粗利益率 | 50.8% |
| 営業利益率 | 5.3% |
| 報告期間 | Q4 2025 |
売上内訳
INTEGRA LIFESCIENCES HOLDINGS CORP Q4 2025 revenue of $434.9M breaks down across 6 segments, led by Neurosurgery at $226.2M (52.0% of total).
| セグメント | 売上高 | 構成比 |
|---|---|---|
| Neurosurgery | $226.2M | 52.0% |
| Asia Pacific | $53.7M | 12.4% |
| Instruments | $52.3M | 12.0% |
| ENT | $44.8M | 10.3% |
| Other | $38.9M | 8.9% |
| Rest Of The World | $19.0M | 4.4% |
INTEGRA LIFESCIENCES HOLDINGS CORP セグメント別売上 — 四半期推移
INTEGRA LIFESCIENCES HOLDINGS CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Neurosurgery and Asia Pacific) has evolved quarter over quarter.
| セグメント | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Neurosurgery | $226.2M | $201.6M | $209.0M | $190.9M |
| Asia Pacific | $53.7M | $42.7M | $47.7M | $45.1M |
| Instruments | $52.3M | $50.2M | $53.1M | — |
| ENT | $44.8M | — | $41.9M | $38.8M |
| Other | $38.9M | — | $44.9M | $31.5M |
INTEGRA LIFESCIENCES HOLDINGS CORP 年度売上推移
INTEGRA LIFESCIENCES HOLDINGS CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.6B). Click any linked year to see what changed vs the prior 10-K.
INTEGRA LIFESCIENCES HOLDINGS CORP 四半期売上・純利益の履歴
INTEGRA LIFESCIENCES HOLDINGS CORP quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q4 2025 | $434.9M | -1.7% | N/A | N/A |
| Q3 2025 | $402.1M | +5.6% | $-5.4M | -1.3% |
| Q2 2025 | $415.6M | -0.6% | $-484.1M | -116.5% |
| Q1 2025 | $382.7M | +3.7% | $-25.3M | -6.6% |
| Q4 2024 | $442.6M | +11.5% | N/A | N/A |
| Q3 2024 | $380.8M | -0.4% | $-10.7M | -2.8% |
| Q2 2024 | $418.2M | +9.7% | $-12.4M | -3.0% |
| Q1 2024 | $368.9M | -3.1% | $-3.3M | -0.9% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $368.9M | $418.2M | $380.8M | $442.6M | $382.7M | $415.6M | $402.1M | $434.9M |
| 前年比成長 | -3.1% | 9.7% | -0.4% | 11.5% | 3.7% | -0.6% | 5.6% | -1.7% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $4.08B | $4.07B | $4.07B | $4.04B | $4.05B | $3.67B | $3.65B | $3.60B |
| 総負債 | $2.48B | $2.54B | $2.54B | $2.49B | $2.53B | $2.63B | $2.61B | $2.56B |
| 株主資本 | $1.60B | $1.53B | $1.52B | $1.55B | $1.52B | $1.04B | $1.04B | $1.04B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $15.8M | $40.4M | $22.5M | $50.7M | $-11.3M | $8.9M | $40.9M | $11.8M |